Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development
Keywords:Anticancer drugs, Antimetastasis drugs, Bioorganometallic, Drug resistance, Glutathione-s-transferase, Ruthenium, Targeted chemotherapy
AbstractOrganometallic ruthenium compounds that are effective anticancer and antimetastasis agents are currently under intensive investigation (see also the article by Peter Sadler in this issue). This article provides a personal account of the way in which we have exploited the different properties of the organoruthenium (and osmium and rhodium) compounds to rival traditional DNA-binding platinum drugs, culminating in the discovery of a non-classical molecule that is in an advanced stage of pre-clinical evaluation.
How to Cite
P. J. Dyson, Chimia 2007, 61, 698, DOI: 10.2533/chimia.2007.698.
Copyright (c) 2007 Swiss Chemical Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.